Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial.

Cremolini C, Marmorino F, Bergamo F, Aprile G, Salvatore L, Masi G, Dell'Aquila E, Antoniotti C, Murgioni S, Allegrini G, Borelli B, Gemma D, Casagrande M, Granetto C, Delfanti S, Di Donato S, Schirripa M, Sensi E, Tonini G, Lonardi S, Fontanini G, Boni L, Falcone A.

Eur J Cancer. 2019 Mar;109:175-182. doi: 10.1016/j.ejca.2018.12.028. Epub 2019 Feb 5.

PMID:
30735919
2.

Optimization of biomarkers-based classification scores as progression-free survival predictors: an intuitive graphical representation.

Manciu M, Hosseini S, Di Desidero T, Allegrini G, Falcone A, Bocci G, Kirken RA, Francia G.

Future Sci OA. 2018 Nov 1;4(10):FSO346. doi: 10.4155/fsoa-2018-0020. eCollection 2018 Dec.

3.

Primary Tumor Sidedness and Benefit from FOLFOXIRI plus Bevacizumab as Initial Therapy for Metastatic Colorectal Cancer.

Cremolini C, Antoniotti C, Lonardi S, Bergamo F, Cortesi E, Tomasello G, Moretto R, Ronzoni M, Racca P, Loupakis F, Zaniboni A, Tonini G, Buonadonna A, Marmorino F, Allegrini G, Granetto C, Masi G, Zagonel V, Sensi E, Fontanini G, Boni L, Falcone A.

Ann Oncol. 2018 Apr 20. doi: 10.1093/annonc/mdy140. [Epub ahead of print]

PMID:
29897402
4.

Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO.

Cremolini C, Antoniotti C, Lonardi S, Bergamo F, Cortesi E, Tomasello G, Moretto R, Ronzoni M, Racca P, Loupakis F, Zaniboni A, Tonini G, Buonadonna A, Marmorino F, Allegrini G, Granetto C, Masi G, Zagonel V, Sensi E, Fontanini G, Boni L, Falcone A.

Ann Oncol. 2018 Apr 20. doi: 10.1093/annonc/mdy140. [Epub ahead of print]

PMID:
29873679
5.

DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer.

Cremolini C, Del Re M, Antoniotti C, Lonardi S, Bergamo F, Loupakis F, Borelli B, Marmorino F, Citi V, Cortesi E, Moretto R, Ronzoni M, Tomasello G, Zaniboni A, Racca P, Buonadonna A, Allegrini G, Ricci V, Di Donato S, Zagonel V, Boni L, Falcone A, Danesi R.

Oncotarget. 2017 Dec 21;9(8):7859-7866. doi: 10.18632/oncotarget.23559. eCollection 2018 Jan 30.

6.

Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO.

Dell'Aquila E, Cremolini C, Zeppola T, Lonardi S, Bergamo F, Masi G, Stellato M, Marmorino F, Schirripa M, Urbano F, Ronzoni M, Tomasello G, Zaniboni A, Racca P, Buonadonna A, Allegrini G, Fea E, Di Donato S, Chiara S, Tonini G, Tomcikova D, Boni L, Falcone A, Santini D.

Ann Oncol. 2018 Apr 1;29(4):924-930. doi: 10.1093/annonc/mdy004.

PMID:
29324972
7.

TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group.

Cremolini C, Marmorino F, Loupakis F, Masi G, Antoniotti C, Salvatore L, Schirripa M, Boni L, Zagonel V, Lonardi S, Aprile G, Tamburini E, Ricci V, Ronzoni M, Pietrantonio F, Valsuani C, Tomasello G, Passardi A, Allegrini G, Di Donato S, Santini D, Falcone A; all the investigators of the Gruppo Oncologico del Nord Ovest.

BMC Cancer. 2017 Jun 9;17(1):408. doi: 10.1186/s12885-017-3360-z.

8.

SAFE trial: an ongoing randomized clinical study to assess the role of cardiotoxicity prevention in breast cancer patients treated with anthracyclines with or without trastuzumab.

Meattini I, Curigliano G, Terziani F, Becherini C, Airoldi M, Allegrini G, Amoroso D, Barni S, Bengala C, Guarneri V, Marchetti P, Martella F, Piovano P, Vannini A, Desideri I, Tarquini R, Galanti G, Barletta G, Livi L.

Med Oncol. 2017 May;34(5):75. doi: 10.1007/s12032-017-0938-x. Epub 2017 Mar 31. Review.

PMID:
28364270
9.

Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer.

Marmorino F, Salvatore L, Barbara C, Allegrini G, Antonuzzo L, Masi G, Loupakis F, Borelli B, Chiara S, Banzi MC, Miraglio E, Amoroso D, Dargenio F, Bonetti A, Martignetti A, Paris M, Tomcikova D, Boni L, Falcone A, Cremolini C.

Br J Cancer. 2017 Jan;116(3):318-323. doi: 10.1038/bjc.2016.413. Epub 2017 Jan 12.

10.

Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.

Cremolini C, Casagrande M, Loupakis F, Aprile G, Bergamo F, Masi G, Moretto R R, Pietrantonio F, Marmorino F, Zucchelli G, Tomasello G, Tonini G, Allegrini G, Granetto C, Ferrari L, Urbani L, Cillo U, Pilati P, Sensi E, Pellegrinelli A, Milione M, Fontanini G, Falcone A.

Eur J Cancer. 2017 Mar;73:74-84. doi: 10.1016/j.ejca.2016.10.028. Epub 2016 Dec 13.

PMID:
27986363
11.

Second-line Erlotinib or Intermittent Erlotinib plus Docetaxel in Male Ex-smokers with Squamous NSCLC: The TALISMAN Randomized Trial.

Gridelli C, Chella A, Valmadre G, Allegrini G, Brighenti M, Bidoli P, Rossi A, Maione P, Migliorino MR, Ricciardi S, DE Marinis F.

Anticancer Res. 2016 Dec;36(12):6535-6540.

PMID:
27919979
12.

Cardiac safety of adjuvant non-pegylated liposomal doxorubicin combined with cyclophosphamide and followed by paclitaxel in older breast cancer patients.

Coltelli L, Fontana A, Lucchesi S, Ginocchi L, Bocci G, Filidei M, Scalese M, Arrighi G, Finale C, Marcucci L, Goletti O, Salvadori B, Ferrarini I, Bona E, Falcone A, Allegrini G.

Breast. 2017 Feb;31:186-191. doi: 10.1016/j.breast.2016.11.006. Epub 2016 Nov 23.

PMID:
27886643
13.

Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patients.

Di Desidero T, Derosa L, Galli L, Orlandi P, Fontana A, Fioravanti A, Marconcini R, Giorgi M, Campi B, Saba A, Lucchesi S, Felipetto R, Danesi R, Francia G, Allegrini G, Falcone A, Bocci G.

Invest New Drugs. 2016 Dec;34(6):760-770. Epub 2016 Aug 24.

PMID:
27557783
14.

FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials.

Cremolini C, Loupakis F, Masi G, Lonardi S, Granetto C, Mancini ML, Chiara S, Moretto R, Rossini D, Vitello S, Allegrini G, Tonini G, Bergamo F, Tomasello G, Ronzoni M, Buonadonna A, Bustreo S, Barbara C, Boni L, Falcone A.

Ann Oncol. 2016 May;27(5):843-9. doi: 10.1093/annonc/mdw052. Epub 2016 Feb 9.

PMID:
26861604
15.

FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.

Cremolini C, Loupakis F, Antoniotti C, Lupi C, Sensi E, Lonardi S, Mezi S, Tomasello G, Ronzoni M, Zaniboni A, Tonini G, Carlomagno C, Allegrini G, Chiara S, D'Amico M, Granetto C, Cazzaniga M, Boni L, Fontanini G, Falcone A.

Lancet Oncol. 2015 Oct;16(13):1306-15. doi: 10.1016/S1470-2045(15)00122-9. Epub 2015 Aug 31.

PMID:
26338525
16.

Genetic interaction of P2X7 receptor and VEGFR-2 polymorphisms identifies a favorable prognostic profile in prostate cancer patients.

Solini A, Simeon V, Derosa L, Orlandi P, Rossi C, Fontana A, Galli L, Di Desidero T, Fioravanti A, Lucchesi S, Coltelli L, Ginocchi L, Allegrini G, Danesi R, Falcone A, Bocci G.

Oncotarget. 2015 Oct 6;6(30):28743-54. doi: 10.18632/oncotarget.4926.

17.

Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial.

Masi G, Salvatore L, Boni L, Loupakis F, Cremolini C, Fornaro L, Schirripa M, Cupini S, Barbara C, Safina V, Granetto C, Fea E, Antonuzzo L, Boni C, Allegrini G, Chiara S, Amoroso D, Bonetti A, Falcone A; BEBYP Study Investigators.

Ann Oncol. 2015 Apr;26(4):724-30. doi: 10.1093/annonc/mdv012. Epub 2015 Jan 18.

PMID:
25600568
18.

Pharmacogenetic interaction analysis of VEGFR-2 and IL-8 polymorphisms in advanced breast cancer patients treated with paclitaxel and bevacizumab.

Allegrini G, Coltelli L, Orlandi P, Fontana A, Camerini A, Ferro A, Cazzaniga M, Casadei V, Lucchesi S, Bona E, Di Lieto M, Pazzagli I, Villa F, Amoroso D, Scalese M, Arrighi G, Molinaro S, Fioravanti A, Finale C, Triolo R, Di Desidero T, Donati S, Marcucci L, Goletti O, Del Re M, Salvadori B, Ferrarini I, Danesi R, Falcone A, Bocci G.

Pharmacogenomics. 2014 Dec;15(16):1985-99. doi: 10.2217/pgs.14.140.

PMID:
25521357
19.

Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.

Loupakis F, Cremolini C, Masi G, Lonardi S, Zagonel V, Salvatore L, Cortesi E, Tomasello G, Ronzoni M, Spadi R, Zaniboni A, Tonini G, Buonadonna A, Amoroso D, Chiara S, Carlomagno C, Boni C, Allegrini G, Boni L, Falcone A.

N Engl J Med. 2014 Oct 23;371(17):1609-18. doi: 10.1056/NEJMoa1403108.

20.

Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers.

Allegrini G, Di Desidero T, Barletta MT, Fioravanti A, Orlandi P, Canu B, Chericoni S, Loupakis F, Di Paolo A, Masi G, Fontana A, Lucchesi S, Arrighi G, Giusiani M, Ciarlo A, Brandi G, Danesi R, Kerbel RS, Falcone A, Bocci G.

Angiogenesis. 2012 Jun;15(2):275-86. doi: 10.1007/s10456-012-9260-6. Epub 2012 Mar 2.

21.

Outcome of second-line treatment after first-line chemotherapy with the GONO FOLFOXIRI regimen.

Fornaro L, Vasile E, Masi G, Loupakis F, Baldi GG, Allegrini G, Salvatore L, Cremolini C, Cupini S, Cortesi E, Tuzi A, Granetto C, Brunetti IM, Ricci S, Falcone A.

Clin Colorectal Cancer. 2012 Mar;11(1):71-6. doi: 10.1016/j.clcc.2011.06.013. Epub 2011 Sep 8.

PMID:
21903485
22.

Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis.

Masi G, Vasile E, Loupakis F, Cupini S, Fornaro L, Baldi G, Salvatore L, Cremolini C, Stasi I, Brunetti I, Fabbri MA, Puglisi M, Trenta P, Granetto C, Chiara S, Fioretto L, Allegrini G, Crinò L, Andreuccetti M, Falcone A.

J Natl Cancer Inst. 2011 Jan 5;103(1):21-30. doi: 10.1093/jnci/djq456. Epub 2010 Dec 1.

PMID:
21123833
23.

Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: clinical outcome according to KRAS and BRAF mutational status.

Fornaro L, Baldi GG, Masi G, Allegrini G, Loupakis F, Vasile E, Cupini S, Stasi I, Salvatore L, Cremolini C, Vincenzi B, Santini D, Tonini G, Graziano F, Ruzzo A, Canestrari E, Magnani M, Falcone A.

Crit Rev Oncol Hematol. 2011 Jun;78(3):243-51. doi: 10.1016/j.critrevonc.2010.06.003. Epub 2010 Jul 8.

PMID:
20619672
24.

Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma.

Loupakis F, Masi G, Fornaro L, Vasile E, Allegrini G, Fontana E, Granetto C, Salvatore L, Mentuccia L, Andreuccetti M, Cortesi E, Merlano M, Cascinu S, Falcone A.

Cancer Chemother Pharmacol. 2010 Aug;66(3):559-66. doi: 10.1007/s00280-009-1196-1. Epub 2010 Mar 17.

PMID:
20237927
25.

Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer.

Fioravanti A, Canu B, Alì G, Orlandi P, Allegrini G, Di Desidero T, Emmenegger U, Fontanini G, Danesi R, Del Tacca M, Falcone A, Bocci G.

Eur J Pharmacol. 2009 Oct 1;619(1-3):8-14. doi: 10.1016/j.ejphar.2009.08.020. Epub 2009 Aug 18.

PMID:
19695243
26.

Discordant somatic and germline VEGF-A genotype in a cancer patient resistant to paclitaxel/bevacizumab with chemosensitive hepatic metastasis.

Coltelli L, Allegrini G, Orlandi P, Giuntini N, Alì G, Fioravanti A, Bona E, Barletta MT, Fontanini G, Del Tacca M, Danesi R, Falcone A, Bocci G.

Pharmacogenomics. 2009 Aug;10(8):1225-9. doi: 10.2217/pgs.09.55.

PMID:
19663667
27.

Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer.

Fontana A, Galli L, Fioravanti A, Orlandi P, Galli C, Landi L, Bursi S, Allegrini G, Fontana E, Di Marsico R, Antonuzzo A, D'Arcangelo M, Danesi R, Del Tacca M, Falcone A, Bocci G.

Clin Cancer Res. 2009 Aug 1;15(15):4954-62. doi: 10.1158/1078-0432.CCR-08-3317. Epub 2009 Jul 21.

28.

Pharmacokinetics, a main actor in a many-sided approach to severe 5-FU toxicity prediction.

Bocci G, Di Paolo A, Barbara C, Masi G, Fornaro L, Loupakis F, Allegrini G, Falcone A, Del Tacca M, Danesi R.

Br J Clin Pharmacol. 2009 Jan;67(1):132-4. doi: 10.1111/j.1365-2125.2008.03307.x. Epub 2008 Nov 5. No abstract available.

29.

Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib.

Bocci G, Falcone A, Fioravanti A, Orlandi P, Di Paolo A, Fanelli G, Viacava P, Naccarato AG, Kerbel RS, Danesi R, Del Tacca M, Allegrini G.

Br J Cancer. 2008 May 20;98(10):1619-29. doi: 10.1038/sj.bjc.6604352. Epub 2008 Apr 29.

30.

A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients.

Allegrini G, Falcone A, Fioravanti A, Barletta MT, Orlandi P, Loupakis F, Cerri E, Masi G, Di Paolo A, Kerbel RS, Danesi R, Del Tacca M, Bocci G.

Br J Cancer. 2008 Apr 22;98(8):1312-9. doi: 10.1038/sj.bjc.6604311. Epub 2008 Mar 25.

31.

Triplet combination of fluoropyrimidines, oxaliplatin, and irinotecan in the first-line treatment of metastatic colorectal cancer.

Masi G, Vasile E, Loupakis F, Bursi S, Ricci S, Petrini I, Fontana A, Allegrini G, Falcone A.

Clin Colorectal Cancer. 2008 Jan;7(1):7-14. doi: 10.3816/CCC.2008.n.002. Review.

PMID:
18279572
32.

Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest.

Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, Crinò L, Benedetti G, Evangelista W, Fanchini L, Cortesi E, Picone V, Vitello S, Chiara S, Granetto C, Porcile G, Fioretto L, Orlandini C, Andreuccetti M, Masi G; Gruppo Oncologico Nord Ovest.

J Clin Oncol. 2007 May 1;25(13):1670-6.

PMID:
17470860
33.

Capecitabine and mitomycin C may be an effective treatment option for third-line chemotherapy in advanced colorectal cancer.

Scartozzi M, Falcone A, Pucci F, Braconi C, Pierantoni C, Cavanna L, Franciosi V, Berardi R, Beretta G, Masi G, Allegrini G, Zaniboni A, Labianca R, Cascinu S.

Tumori. 2006 Sep-Oct;92(5):384-8.

PMID:
17168429
34.

A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity.

Bocci G, Barbara C, Vannozzi F, Di Paolo A, Melosi A, Barsanti G, Allegrini G, Falcone A, Del Tacca M, Danesi R.

Clin Pharmacol Ther. 2006 Oct;80(4):384-95.

PMID:
17015056
35.

First-line 5-fluorouracil/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) does not impair the feasibility and the activity of second line treatments in metastatic colorectal cancer.

Masi G, Marcucci L, Loupakis F, Cerri E, Barbara C, Bursi S, Allegrini G, Brunetti IM, Murr R, Ricci S, Cupini S, Andreuccetti M, Falcone A.

Ann Oncol. 2006 Aug;17(8):1249-54. Epub 2006 Jun 9.

PMID:
16766580
36.

Irinotecan in combination with thalidomide in patients with advanced solid tumors: a clinical study with pharmacodynamic and pharmacokinetic evaluation.

Allegrini G, Di Paolo A, Cerri E, Cupini S, Amatori F, Masi G, Danesi R, Marcucci L, Bocci G, Del Tacca M, Falcone A.

Cancer Chemother Pharmacol. 2006 Nov;58(5):585-93. Epub 2006 May 6.

PMID:
16680463
37.

Treatment with 5-fluorouracil/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer.

Masi G, Cupini S, Marcucci L, Cerri E, Loupakis F, Allegrini G, Brunetti IM, Pfanner E, Viti M, Goletti O, Filipponi F, Falcone A.

Ann Surg Oncol. 2006 Jan;13(1):58-65. Epub 2006 Jan 1.

PMID:
16372158
38.

First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule.

Masi G, Allegrini G, Cupini S, Marcucci L, Cerri E, Brunetti I, Fontana E, Ricci S, Andreuccetti M, Falcone A.

Ann Oncol. 2004 Dec;15(12):1766-72.

PMID:
15550581
39.

A phase I and pharmacokinetic study of irinotecan given as a 7-day continuous infusion in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed.

Masi G, Falcone A, Di Paolo A, Allegrini G, Danesi R, Barbara C, Cupini S, Del Tacca M.

Clin Cancer Res. 2004 Mar 1;10(5):1657-63.

40.

5-fluorouracil administered as a 48-hour semiintermittent infusion in combination with leucovorin, cisplatin and epirubicin: phase II study in advanced gastric cancer patients.

Allegrini G, Falcone A, Di Marsico R, Lencioni M, Masi G, Galli C, Cupini S, Pfanner E, Marcucci L, Conte PF.

Am J Clin Oncol. 2004 Feb;27(1):101-5.

PMID:
14758142
41.

Thrombospondin-1 plus irinotecan: a novel antiangiogenic-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice.

Allegrini G, Goulette FA, Darnowski JW, Calabresi P.

Cancer Chemother Pharmacol. 2004 Mar;53(3):261-6. Epub 2003 Dec 5.

PMID:
14658007
42.

Severe 5-fluorouracil toxicity associated with a marked alteration of pharmacokinetics of 5-fluorouracil and its catabolite 5-fluoro-5,6-dihydrouracil: a case report.

Bocci G, Danesi R, Allegrini G, Innocenti F, Di Paolo A, Falcone A, Conte PF, Del Tacca M.

Eur J Clin Pharmacol. 2002 Dec;58(9):593-5.

PMID:
12602342
43.

Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer.

Falcone A, Masi G, Allegrini G, Danesi R, Pfanner E, Brunetti IM, Di Paolo A, Cupini S, Del Tacca M, Conte P.

J Clin Oncol. 2002 Oct 1;20(19):4006-14.

PMID:
12351598
44.

Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients.

Di Paolo A, Danesi R, Falcone A, Cionini L, Vannozzi F, Masi G, Allegrini G, Mini E, Bocci G, Conte PF, Del Tacca M.

Ann Oncol. 2001 Sep;12(9):1301-6.

PMID:
11697844
45.

Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients.

Falcone A, Di Paolo A, Masi G, Allegrini G, Danesi R, Lencioni M, Pfanner E, Comis S, Del Tacca M, Conte P.

J Clin Oncol. 2001 Aug 1;19(15):3456-62.

PMID:
11481350
46.

5-fluorouracil administered as a 48-hour chronomodulated infusion in combination with leucovorin and cisplatin: a randomized phase II study in metastatic colorectal cancer.

Falcone A, Allegrini G, Masi G, Lencioni M, Pfanner E, Brunetti I, Danesi R, Bocci G, Del Tacca M, Conte P.

Oncology. 2001;61(1):28-35.

PMID:
11474245
47.

[Continuous versus intermittent infusion in chemotherapy of colorectal cancer].

Falcone A, Masi G, Allegrini G, Cupini S.

Tumori. 2001 Jan-Feb;87(1 Suppl 1):S45-6. Italian. No abstract available.

PMID:
11300022
48.

Oral doxifluridine in advanced hepatocellular carcinoma: A phase II study.

Lencioni M, Falcone A, Allegrini G, Pfanner E, Masi G, Brunetti I, Di Marsico R, Fontana E, Orlandini C, Stampino CG, Bartolozzi C, Conte PF.

Oncology. 2000 Sep;59(3):204-9.

PMID:
11053987
49.

Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients.

Bocci G, Danesi R, Di Paolo AD, Innocenti F, Allegrini G, Falcone A, Melosi A, Battistoni M, Barsanti G, Conte PF, Del Tacca M.

Clin Cancer Res. 2000 Aug;6(8):3032-7.

50.

Infusions of fluorouracil and leucovorin: effects of the timing and semi-intermittency of drug delivery.

Falcone A, Allegrini G, Antonuzzo A, Brunetti I, Pfanner E, Lencioni M, Masi G, Danesi R, Del Tacca M, Conte P.

Oncology. 1999 Oct;57(3):195-201.

PMID:
10545787

Supplemental Content

Loading ...
Support Center